非小细胞肺癌术后分子靶向治疗研究进展  

Research Progress of Postoperative Molecular Target Therapy for Non-small Cell Lung Cancer

作　　者：李才[1] 田作春[1] 

机构地区：[1]海南省农垦三亚医院心胸外科,海南三亚572000

出　　处：《医学综述》2015年第18期3313-3315,共3页Medical Recapitulate

摘　　要：化疗在晚期非小细胞肺癌治疗上的疗效已达一个平台,且毒性作用限制了化疗的进一步发展。随着对现代肿瘤分子生物学及基因水平的认识逐渐加深,靶向治疗以成为临床研究的重点,非小细胞肺癌术后给予分子靶向治疗已成为目前抗肿瘤研究的热点。靶向治疗是在细胞分子水平上,针对明确的致癌位点,设计相应的治疗药物,使药物进入体内特异性选择致癌位点结合而发生作用,从而最终使肿瘤细胞特异性死亡,正常组织细胞不受影响的一种治疗方法。常用的分子靶向治疗药物包括表皮生长因子受体抑制剂,抗血管生成药物,多靶点药物等。In the treatment of advanced non-small cell lung cancer,curative effect of chemotherapy has encountered the platform stage,and toxic effects restrict the further development of chemotherapy. As the molecular biology and gene level understanding of modern tumor is gradually deepened,targeted therapy has become the focus of the clinical research,and molecular targeted therapy after non-small cell lung cancer surgery has become the hotspot in the anti-tumor research. The targeted therapy is directed to a specific cancer sites on the cell molecular level,to design the corresponding drug,and make the drug to combine and interact with specific cancer sites in vivo,so as to eventually make specific death of tumor cells,without affecting normal cells. The commonly used molecular targeted drugs include the epidermal growth factor receptor inhibitor,anti-angiogenesis drugs,multiple-target drugs etc.

关 键 词：非小细胞肺癌 术后 分子靶向治疗 

分 类 号：R734.2[医药卫生—肿瘤]